Assets replicating Scientific Beta's multi-factor indices

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
27
Assets replicating Scientific Beta's multi-factor indices reach USD 43bn

Scientific Beta sees its assets under replication grow by 72% in one year

Scientific Beta has announced that assets tracking its smart beta indices reached USD 43bn at December 31, 2018. Compared to December 31, 2017, this amount of assets under replication represents an increase of USD 18bn, corresponding to one-year growth of 72%.

This growth comes from the success of Scientific Beta’s multi-factor offerings. The Scientific Beta Multi-Beta Multi-Strategy Four-Factor EW indices, which were the first multi-factor indices to be offered by Scientific Beta, show an average live annualised outperformance across all Scientific Beta Developed regions of 1.49% over their five-year live track record and an improvement in Sharpe Ratio of 52.36% compared to their cap-weighted benchmark 1 .

Noël Amenc, CEO of Scientific Beta, said, “We have been very pleased with the continued growth of our assets under replication in conditions that were not necessarily favourable for some factor strategies. We are continuing to highlight the importance for our clients of risk management in the factor space.

Smart beta strategies are selected to provide explicit exposure to some well-rewarded factors (Value, Momentum, Low Volatility, Profitability, Low Investment, Size). These factors provide good risk-adjusted returns over the long-term but they are also exposed to a number of hidden or implicit risks that drive short-term performance, like for example sector risk or even a market beta bias. These risks can therefore cause big disappointments for investors if they are not understood and possibly managed. These issues have been underlined in a recent Scientific Beta publication entitled Misconceptions and Mis-selling in Smart Beta: Improving the Risk Conversation in the Smart Beta Space . One of our success factors is to analyse these risks, make them explicit and allow investors to hedge them or not depending on their fiduciary objectives and constraints.”

1 The average live outperformance and improvement in Sharpe Ratio across all Scientific Beta developed regions of Scientific Beta Multi-Beta Multi-Strategy Equal-Weight indices is 1.49% for the outperformance and 52.36% for the improvement in Sharpe Ratio. This live analysis is based on daily total returns in the period from December 20, 2013 (live date) to December 31, 2018 for all diversified multi-strategy indices that have more than 3 years of track record for all available developed world regions - USA, Eurozone, UK, Developed Europe, Developed Europe ex UK, Japan, Developed Asia Pacific ex Japan, Developed ex UK, Developed ex USA and Developed. The benchmark used is a cap-weighted portfolio of all stocks in the respective Scientific Beta universes.

 

About ERI Scientific Beta

As part of its policy of transferring know-how to the industry, EDHEC-Risk Institute has set up ERI Scientific Beta. ERI Scientific Beta is an original initiative which aims to favour the adoption of the latest advances in smart beta design and implementation by the whole investment industry. Its academic origin provides the foundation for its strategy: offer, in the best economic conditions possible, the smart beta solutions that are most proven scientifically with full transparency of both the methods and the associated risks.

Find out more by following ERI Scientific Beta on Twitter ( https://twitter.com/ScientificBeta ), LinkedIn ( https://www.linkedin.com/company/scientific-beta ) and YouTube ( https://www.youtube.com/channel/UCRL91F-LvhLPc9M9OD7LQgA) .

ERI Scientific Beta, 1 George Street, #15-02, Singapore 049145. Web:  www.scientificbeta.com , E-mail:  contact@scientificbeta.com .

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

U Power Limited Advances Electric Vehicle Solutions in Europe

Updated Category News Views 239

U Power Limited Expands Its European Reach U Power Limited (Nasdaq: UCAR) is making significant strides in the electric vehicle (EV) landscape. The company, known for its innovative battery-swapping technology, has announced an exciting joint venture that enhances their presence in the European market. This strategic move is expected to reshape how electric mobility is...

Continue Reading
UKG Stands Out as a Top Leader in Workforce Management Solutions

Updated Category News Views 163

UKG Secures Top Spot in Workforce Management UKG, a leading provider in HR, payroll, workforce management, and cultural solutions, has recently earned recognition for its exceptional contributions to the workforce management field. The company has been named a Leader in the NelsonHall New World Workforce Management 2024 evaluation, showcasing its strong performance across...

Continue Reading
Prominent Movers in Today's Market: Micron, Accenture Rise

Updated Category News Views 141

As the trading day unfolds, the US stock market is witnessing a shift, with several companies experiencing significant movements in their stock prices. Recent trends show that investors are closely monitoring the market after a minor disruption in gains. Micron's Robust Performance Micron Technology (NASDAQ: MU) has captured the spotlight today, with shares surging by an...

Continue Reading
Celebrate 1.5 Years of Obey Me! Nightbringer with Exciting Events

Updated Category News Views 85

Celebrating 1.5 Years of Obey Me! Nightbringer Obey Me! Nightbringer is reaching a significant milestone, celebrating its 1.5-year anniversary. This beloved mobile game from NTT Solmare has captured the hearts of players around the globe, and to acknowledge this momentous occasion, the developers are rolling out a variety of exciting events. Four Exciting Events for...

Continue Reading
Celebrating Innovation: 2026 sofi™ Awards Winners Unveiled

Updated Category News Views 219

Celebrating Culinary Excellence: The 2026 sofi™ Awards NEW YORK — The Specialty Food Association (SFA) revealed the much-anticipated results of the 2026 sofi™ Awards at the Winter FancyFaire event. This celebrated gathering brought together industry leaders, chefs, makers, and buyers to applaud the finest in specialty food and beverage innovation. A Night of...

Continue Reading